Ricevi le ultime notizie sulle azioni Mind Medicine con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di MNMD

Ultime notizie per

Mind Medicine

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine Inc

Press Releases

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

MindMed Announces New Employee Inducement Grants

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

MindMed to Participate in June Investor Conferences

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

MindMed Reports Q2 2025 Financial Results and Business Updates

ATAI

CMPS

CYBN

MNMD

SAGE

Alumis

ALT5 Sigma

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Arvinas

ATAI Life Sciences

Cormedix

Cronos Group

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Maze Therapeutics

MBX Biosciences

Nektar Therapeutics

Nuvation Bio

Oculis Holding

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Trevi Therapeutics

Zevra Therapeutics

Oppenheimer

Chardan Capital

Baird

HC Wainwright & Co.

Evercore ISI Group

MiniMed

Comments

Mind Medicine Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO